Denteric’s GPV381 enters Phase 2, but can a therapeutic vaccine really change periodontitis care?
Denteric’s GPV381 has entered Phase 2 in periodontitis. Read why the gingipain-targeting vaccine could test a new treatment model.
Pharma & Biotech
Pharma & Biotech
Lupin Limited moves closer to the Wakix market as pitolisant tentative approval sharpens future optionality
Lupin Limited has won tentative FDA approval for pitolisant tablets. Read why timing, exclusivity, and Wakix market dynamics matter next.
Medical Devices & Diagnostics
Can smaller eyedrops improve glaucoma outcomes? Nanodropper data make the case
Nanodropper’s glaucoma study suggests microdrops may improve pressure control and reduce waste. Read what this could mean for eye care.
How Piramal Pharma Solutions’ Morpeth tablet press upgrade sharpens its play in potent oral solid manufacturing
Piramal Pharma Solutions has added new high-containment tablet capacity at Morpeth. Read what this could change for CDMO competition and potent drug supply.
Pharma & Biotech
Why GC Biopharma’s BARYCELA approval in Guatemala matters beyond one Latin American market
GC Biopharma won Guatemala approval for BARYCELA. Read what this means for Latin America, vaccine supply strategy, and varicella market competition.
Pharma & Biotech
Why Norgine’s PEDMARQSI approval in Switzerland could reshape cisplatin ototoxicity management
Swissmedic approved PEDMARQSI for cisplatin-related hearing loss in children. Read why this could reshape paediatric oncology supportive care.
Pharma & Biotech
Can Ono Pharmaceutical bring clearer treatment sequencing to advanced GIST in Japan?
Ono Pharmaceutical has filed ripretinib in Japan for advanced GIST. Read why the move could reshape late-line treatment access and sequencing.
Medical Devices & Diagnostics
What Invivoscribe’s IdentiClone Dx IGH approval reveals about the new economics of IVDR-ready hematology diagnostics
Invivoscribe’s IdentiClone Dx IGH won IVDR certification in the EU. Read what this means for clonality testing, lab adoption, and diagnostic competition.
Medical Devices & Diagnostics
Imperative Care begins CLEAR-IT study as peripheral thrombectomy moves from device adoption to evidence scrutiny
Imperative Care’s CLEAR-IT study could reshape peripheral thrombectomy standards. Read why its real-world data strategy matters now.
Pharma & Biotech
How Tempus AI and Daiichi Sankyo are using real-world data to reshape antibody-drug conjugate development
Tempus AI and Daiichi Sankyo are using multimodal AI to refine ADC trial strategy and biomarker discovery. Read what this could change next.